Spero Therapeutics Reports Director/Officer Changes & Shareholder Votes
Ticker: SPRO · Form: 8-K · Filed: Jun 18, 2025 · CIK: 1701108
| Field | Detail |
|---|---|
| Company | Spero Therapeutics, Inc. (SPRO) |
| Form Type | 8-K |
| Filed Date | Jun 18, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, officer-changes, director-changes, shareholder-vote
Related Tickers: SPRO
TL;DR
Spero Therapeutics (SPRO) filed an 8-K detailing director/officer changes and shareholder votes.
AI Summary
Spero Therapeutics, Inc. filed an 8-K on June 18, 2025, reporting events that occurred on June 12, 2025. The filing indicates changes related to the departure of directors or certain officers, the election of directors, the appointment of certain officers, and compensatory arrangements for certain officers. It also covers the submission of matters to a vote of security holders.
Why It Matters
Changes in board and officer composition can signal shifts in company strategy or governance, while shareholder votes directly impact corporate decisions.
Risk Assessment
Risk Level: medium — Changes in directors and officers, along with shareholder votes, can indicate internal shifts or strategic decisions that may impact the company's future performance.
Key Players & Entities
- Spero Therapeutics, Inc. (company) — Registrant
- June 12, 2025 (date) — Earliest event reported
- June 18, 2025 (date) — Date of report
FAQ
What specific changes occurred regarding directors or officers on June 12, 2025?
The filing indicates the departure of directors or certain officers, the election of directors, and the appointment of certain officers.
Were there any changes to compensatory arrangements for officers?
Yes, the filing explicitly mentions 'Compensatory Arrangements of Certain Officers' as an item of information.
What matters were submitted to a vote of security holders?
The filing states that 'Submission of Matters to a Vote of Security Holders' is an item of information covered.
What is Spero Therapeutics' principal executive office address?
The address is 675 Massachusetts Avenue, 14th Floor, Cambridge, Massachusetts 02139.
What is Spero Therapeutics' fiscal year end?
Spero Therapeutics' fiscal year ends on December 31st.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on June 18, 2025 regarding Spero Therapeutics, Inc. (SPRO).